Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

AKTS – Akoustis Technologies Inc

Float Short %

0.71

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

-0.04

EPS Last/This Y

1.44

EPS This/Next Y

0.25

Price

0.04

Target Price

31.67

Analyst Recom

1

Performance Q

Upside

N/A

Beta

Ticker: AKTS




19 items of 1

DateSymbolLatestP/C OIP/C VolTotal OI
2026-01-23AKTS21.65N/AN/A0
2026-01-26AKTS21.64N/AN/A0
2026-01-27AKTS21.13N/AN/A0
2026-01-28AKTS20.47N/AN/A0
2026-01-29AKTS19.64N/AN/A0
2026-01-30AKTS20.18N/AN/A0
2026-02-02AKTS21.96N/AN/A0
2026-02-03AKTS20.82N/AN/A0
2026-02-04AKTS19.89N/AN/A0
2026-02-05AKTS19.52N/AN/A0
2026-02-06AKTS18.91N/AN/A0
2026-02-09AKTS18.98N/AN/A0
2026-02-10AKTS17.86N/AN/A0
2026-02-11AKTS18.08N/AN/A0
2026-02-12AKTS17.93N/AN/A0
2026-02-13AKTS17.77N/AN/A0
2026-02-17AKTS17.91N/AN/A0
2026-02-18AKTS17.73N/AN/A0
2026-02-20AKTS18.9N/AN/A0
DateSymbolLatestP/C OIP/C VolTotal OI
19 items Current Page1 of 1




No data found




19 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2026-01-23AKTS18.495.540
2026-01-26AKTS18.495.540
2026-01-27AKTS18.495.540
2026-01-28AKTS34.855.540.17
2026-01-29AKTS34.855.540.17
2026-01-30AKTS34.855.540.17
2026-02-02AKTS34.855.540.17
2026-02-03AKTS34.855.540.17
2026-02-04AKTS34.855.540.17
2026-02-05AKTS34.855.540.17
2026-02-06AKTS34.855.540.17
2026-02-10AKTS34.855.540.17
2026-02-11AKTS34.855.540.70
2026-02-12AKTS34.175.540.71
2026-02-13AKTS34.175.540.71
2026-02-17AKTS34.175.540.71
2026-02-18AKTS34.175.540.71
2026-02-19AKTS34.175.540.71
2026-02-20AKTS34.175.540.71
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
19 items Current Page1 of 1

Last Quarter Act. EPS

-0.04

Avg. EPS Est. Current Quarter

-0.07

Avg. EPS Est. Next Quarter

-0.07

Insider Transactions

34.17

Institutional Transactions

5.54

Beta

Average Sales Estimate Current Quarter

9

Average Sales Estimate Next Quarter

10

Fair Value

Quality Score

54

Growth Score

48

Sentiment Score

13

Actual DrawDown %

99.8

Max Drawdown 5-Year %

-99.8

Target Price

31.67

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

-0.45

EPS Next Y. (Est.)

-0.2

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

0.64

Return on Equity vs Sector %

183.5

Return on Equity vs Industry %

216.6

EPS 1 7Days Diff

-0.1

EPS 1 30Days Diff

-0.09

EBIT Estimation

Aktis Oncology, Inc.
Sector: Healthcare
Industry: Biotechnology
Employees:
Aktis Oncology, Inc. operates as a clinical-stage oncology company that engages in the development of targeted radiopharmaceutical therapies for cancer treatment. The company offers a miniprotein radioconjugate platform to discover and develop radiopharmaceutical therapies that deliver the tumor-killing properties of radioisotopes. It offers Nectin-4, a miniprotein radioconjugate for the treatment of locally advanced or metastatic urothelial cancer. Its products include AKY-1189 to deliver a radioisotope to Nectin-4 expressing tumors for the treatment of metastatic urothelial cancer, breast cancer, NSCLC, colorectal cancer and cervical cancer; and AKY-2519 to deliver radioisotope to B7-H3 CD276 expressing tumors targeting prostate, lung and other solid tumors. The company was formerly known as HotKnot Therapeutics, Inc. and changed its name to Aktis Oncology, Inc. in April 2020. Aktis Oncology, Inc. was incorporated in 2020 and is based in Boston, Massachusetts.
stock quote shares AKTS – Akoustis Technologies Inc Stock Price stock today
news today AKTS – Akoustis Technologies Inc stock forecast ,stock prediction 2023 2024 2025
marketwatch AKTS – Akoustis Technologies Inc yahoo finance google finance
stock history AKTS – Akoustis Technologies Inc invest stock market
stock prices AKTS premarket after hours
ticker AKTS fair value insiders trading